Maternal use of selective serotonin reuptake inhibitors during pregnancy and neonatal bone density

Early Human Development

Volumn 88, Issue 3, 2012, Pages 191-194

  Dubnov Raz, Gal ^a,b   Hemilä, Harri ^c   Vurembrand, Yael ^a   Kuint, Jacob ^a,b   Maayan Metzger, Ayala ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Antenatal; Bone; Infants; SSRI; Ultrasound

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ANTHROPOMETRY; ARTICLE; BIRTH WEIGHT; BONE DENSITY; BONE STRENGTH; CONTROLLED STUDY; DRUG MEGADOSE; ECHOGRAPHY; FEMALE; GESTATIONAL AGE; GROWTH; HEAD CIRCUMFERENCE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOTHER; NEONATAL BONE DENSITY; NEWBORN; PREGNANCY; PRENATAL DRUG EXPOSURE; TIBIA;

BONE DENSITY; CASE-CONTROL STUDIES; FEMALE; HUMANS; INFANT, NEWBORN; MATERNAL EXPOSURE; PREGNANCY; SEROTONIN UPTAKE INHIBITORS;

EID: 84857121124     PISSN: 03783782     EISSN: 18726232     Source Type: Journal    
DOI: 10.1016/j.earlhumdev.2011.08.005     Document Type: Article

References (36)

1. Gavin N.I., Gaynes B.N., Lohr K.N., Meltzer-Brody S., Gartlehner G., Swinson T. Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 2005, 106:1071-1083.
2. Marcus S.M., Flynn H.A., Blow F.C., et al. Depressive symptoms among pregnant women screened in obstetrics settings. J Women's Health 2003, 12:373-380.
3. Reefhuis J., Rasmussen S.A., Friedman J.M. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 2006, 354:2188-2189.
4. Hendrick V., Stowe Z.N., Altshuler L.L., Hwang S., Lee E., Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003, 160:993-996.
5. Lund N., Pedersen L.H., Henriksen T.B. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009, 163:949-954.
6. Ferreira E., Carceller A.M., Agogué C., et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates. Pediatrics 2007, 119:52-59.
7. Oberlander T.F., Warburton W., Misri S. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006, 63:898-906.
8. Alwan S., Reefhuis J., Rasmussen S.A., Olney R.S., Friedman J.M. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007, 356:2684-2692.
9. Tuccori M., Testi A., Antonioli L., Fornai M., Montagnani S., Ghisu N., Colucci R., Corona T., Blandizzi C., Del Tacca M. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review. Clin Ther 2009, 31(Pt 1):1426-1453.
10. Wen S.W., Yang Q., Garner P., Fraser W., Olatunbosun O., Nimrod C., Walker M. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006, 194:961-966.
11. Källén B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004, 158:312-316.
12. Dubnov-Raz G., Juurlink D.N., Fogelman R., Merlob P., Ito S., Koren G., Finkelstein Y. Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 2008, 122:e710-e715.
13. Chambers C.D., Johnson K.A., Dick L.M., Felix R.J., Jones K.L. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996, 335:1010-1015.
14. Davidson S., Prokonov D., Taler M., Maayan R., Harell D., Gil-Ad I., Weizman A. Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr Res 2009, 65:236-241.
15. Warden S.J., Robling A.G., Sanders M.S., Bliziotes M.M., Turner C.H. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005, 146:685-693.
16. Westbroek I., Waarsing J.H., van Leeuwen J.P., Waldum H., Reseland J.E., Weinans H., Syversen U., Gustafsson B.I. Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats. J Cell Biochem 2007, 101:360-368.
17. Richards J.B., Papaioannou A., Adachi J.D., Joseph L., Whitson H.E., Prior J.C., Goltzman D. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007, 167:188-194.
18. Haney E.M., Chan B.K., Diem S.J., Ensrud K.E., Cauley J.A., Barrett-Connor E., Orwoll E., Bliziotes M.M. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007, 167:1246-1251. for the Osteoporotic Fractures in Men Study Group.
19. Diem S.J., Blackwell T.L., Stone K.L., Yaffe K., Haney E.M., Bliziotes M.M., Ensrud K.E. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007, 167:1240-1245.
20. Bolton J.M., Targownik L.E., Leung S., Sareen J., Leslie W.D. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. J Clin Psychopharmacol 2011, 31:56-60.
21. Verdel B.M., Souverein P.C., Egberts T.C., van Staa T.P., Leufkens H.G., de Vries F. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 2010, 47:604-609.
22. Calarge C.A., Zimmerman B., Xie D., Kuperman S., Schlechte J.A. A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 2010, 71:338-347.
23. Weintrob N., Cohen D., Klipper-Aurbach Y., Zadik Z., Dickerman Z. Decreased growth during therapy with selective serotonin reuptake inhibitors. Arch Pediatr Adolesc Med 2002, 156:696-701.
24. Tsapakis E.M., Gamie Z., Tran G.T., Adshead S., Lampard A., Mantalaris A., Tsiridis E. The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 2011 Feb 2, [Epub ahead of print].
25. Nemet D., Dolfin T., Wolach B., Eliakim A. Quantitative ultrasound measurements of bone speed of sound in premature infants. Eur J Pediatr 2001, 160:736-740.
26. Dollberg S., Haklai Z., Mimouni F.B., Gorfein I., Gordon E.S. Birth weight standards in the live-born population in Israel. Isr Med Assoc J 2005, 7:311-314.
27. Litmanovitz I., Dolfin T., Friedland O., Arnon S., Regev R., Shainkin-Kestenbaum R., Lis M., Eliakim A. Early physical activity intervention prevents decrease of bone strength in very low birth weight infants. Pediatrics 2003, 112:15-19.
28. Regev R.H., Dolfin T., Eliakim A., Arnon S., Bauer S., Nemet D., Litmanovitz I. Bone speed of sound in infants of mothers with gestational diabetes mellitus. J Pediatr Endocrinol Metab 2004, 17:1083-1088.
29. Littner Y., Mandel D., Mimouni F.B., Dollberg S. Decreased bone ultrasound velocity in large-for-gestational-age infants. J Perinatol 2004, 24:21-23.
30. McDevitt H., Ahmed S.F. Quantitative ultrasound assessment of bone health in the neonate. Neonatology 2007, 91:2-11.
31. Battaglino R., Fu J., Späte U., Ersoy U., Joe M., Sedaghat L., Stashenko P. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004, 19:1420-1431.
32. Javaid M.K., Godfrey K.M., Taylor P., Shore S.R., Breier B., Arden N.K., Cooper C. Umbilical venous IGF-1 concentration, neonatal bone mass, and body composition. J Bone Miner Res 2004, 19:56-63.
33. Bliziotes M. Update in serotonin and bone. J Clin Endocrinol Metab 2010, 95:4124-4132.
34. Cooke R., Lucas A., Yudkin P., Pryse-Davies J. Head circumference as an index of brain weight in the fetus and newborn. Early Hum Dev 1977, 1:145-149.
35. Cheong J.L., Hunt R.W., Anderson P.J., Howard K., Thompson D.K., Wang H.X., Bear M.J., Inder T.E., Doyle L.W. Head growth in preterm infants: correlation with magnetic resonance imaging and neurodevelopmental outcome. Pediatrics 2008, 121:e1534-e1540.
36. Klinger G., Frankenthal D., Merlob P., Diamond G., Sirota L., Levinson-Castiel R., Linder N., Stahl B., Inbar D. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol 2011 Feb 10, [Epub ahead of print].